Novartis/Hexal: Generic Consolidation, and More
Executive Summary
Buying Hexal shows Novartis' commitment to generics. The Swiss group also hopes the move will bring more credibility, and better deals, across all of its businesses.
You may also be interested in...
Is Teva Among Finalists In Bidding For Germany's Ratiopharm? (Part 2 of 2)
Ratiopharm would bring market share, geographic diversification, and an attractive OTC business - if the price is right.
Not-For-Profit Makes Business Sense, Too
Not-for-profit drug development and other charitable initiatives haven't had a hugely prominent role at Big Pharma in the past. But nowadays most Big Pharma can point to some sort of benevolent effort, and a few companies view such initiatives as more than just the right thing to do. They claim that not-for-profit R&D makes good business sense, too.
Not-For-Profit Makes Business Sense, Too
Not-for-profit drug development and other charitable initiatives haven't had a hugely prominent role at Big Pharma in the past. But nowadays most Big Pharma can point to some sort of benevolent effort, and a few companies view such initiatives as more than just the right thing to do. They claim that not-for-profit R&D makes good business sense, too.